Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ros Eeles

Showing results (1-10 of 75) with videos related to

Pageof 8
Sort By:
Cold Spring Harbor Perspectives in Medicine|November 5, 2017
Prostate Cancer Germline Variations and Implications for Screening and TreatmentAlexander Dias, Zsofia Kote-Jarai, Christos Mikropoulos, et al.
Human Mutation|May 15, 2002
The IARC TP53 database: new online mutation analysis and recommendations to usersMagali Olivier, Ros Eeles, Monica Hollstein, et al.
BJU International|April 21, 2005
Early outcomes of active surveillance for localized prostate cancerClaire Hardie, Chris Parker, Andrew Norman, et al.
Sociology of Health & Illness|December 14, 2006
Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their familyNina Hallowell, Audrey Arden-Jones, Ros Eeles, et al.
Psycho-Oncology|December 19, 2003
Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinicKathleen Lintz, Clare Moynihan, Suzanne Steginga, et al.
Plos Medicine|December 21, 2019
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling studyTom Callender, Mark Emberton, Steve Morris, et al.
Prostate Cancer and Prostatic Diseases|November 29, 2019
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECTMahbubl Ahmed, Chee Goh, Edward Saunders, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2004
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatmentJulie Shorrocks, Simon E Tobi, Harry Latham, et al.
Familial Cancer|October 17, 2007
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)Johanne Geary, Peter Sasieni, Richard Houlston, et al.
The Journal of Pathology. Clinical Research|February 25, 2021
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancerDavid Gonzalez, Joaquin Mateo, Albrecht Stenzinger, et al.
Pageof 8

Showing results (1-10 of 75) with videos related to

Sort By:
Pageof 8
Cold Spring Harbor Perspectives in Medicine|November 5, 2017
Prostate Cancer Germline Variations and Implications for Screening and TreatmentAlexander Dias, Zsofia Kote-Jarai, Christos Mikropoulos, et al.
Human Mutation|May 15, 2002
The IARC TP53 database: new online mutation analysis and recommendations to usersMagali Olivier, Ros Eeles, Monica Hollstein, et al.
BJU International|April 21, 2005
Early outcomes of active surveillance for localized prostate cancerClaire Hardie, Chris Parker, Andrew Norman, et al.
Sociology of Health & Illness|December 14, 2006
Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their familyNina Hallowell, Audrey Arden-Jones, Ros Eeles, et al.
Psycho-Oncology|December 19, 2003
Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinicKathleen Lintz, Clare Moynihan, Suzanne Steginga, et al.
Plos Medicine|December 21, 2019
Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling studyTom Callender, Mark Emberton, Steve Morris, et al.
Prostate Cancer and Prostatic Diseases|November 29, 2019
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECTMahbubl Ahmed, Chee Goh, Edward Saunders, et al.
International Journal of Radiation Oncology, Biology, Physics|January 31, 2004
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatmentJulie Shorrocks, Simon E Tobi, Harry Latham, et al.
Familial Cancer|October 17, 2007
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC)Johanne Geary, Peter Sasieni, Richard Houlston, et al.
The Journal of Pathology. Clinical Research|February 25, 2021
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancerDavid Gonzalez, Joaquin Mateo, Albrecht Stenzinger, et al.
Pageof 8